Petricoin receives funding for study focused on discovering cancer protein biomarkers

Emanuel Petricoin, III, Co-Director, Center for Applied Proteomics and Molecular Medicine (CAPMM), received $280,696 from Gateway for Cancer Research for: “Discovery of Protein Biomarkers for Response Prediction to Novel Phase II Targeted Therapy Agents for Stage II/III Breast Cancer Patients in the ISPY2 TRIAL.” This funding began in October 2020 and will end in late…

New drug candidate for the treatment of COVID-19

Researchers from the University of Kent, the Goethe-University in Frankfurt am Main (Germany), and the Hannover Medical School (Germany) have identified a drug with the potential to provide a treatment for COVID-19. The international team led by Professor Martin Michaelis, Dr Mark Wass (both School of Biosciences, University of Kent), and Professor Jindrich Cinatl (Institute…

Can glucose-lowering drugs impact mortality in COVID-19 patients with type 2 diabetes?

CAMBRIDGE, MA – October 27, 2020— In a preprint paper, “Impact of Glucose-Lowering Drugs on Mortality and Other Adverse Outcomes in Patients with Type 2 Diabetes Admitted for COVID-19,” researchers conclude a neutral effect on mortality and other adverse outcomes. Though, given the close relationship between diabetes and COVID-19, they call for more prospective studies.…